4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

doi:10.1001/jama.2026.7399

May 18, 2026JAMA

4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to determine if a 4% tetrasodium EDTA locking fluid can decrease complications associated with central venous access devices in adult ICU patients.
Study comparing 4% tetrasodium EDTA locking fluid with standard care
Conducted in intensive care units with adult patients
Evaluated the rates of CVAD complications
Introduction of 4% tetrasodium EDTA significantly reduced the rate of CVAD complications compared to usual care
Exact event rates and statistical metrics were not provided, but outcomes favored the tetrasodium EDTA group

Implication

Evaluates tetrasodium EDTA effectiveness in reducing CVAD complications in adults, suggesting potential benefits for patient care.

Abstract

This study evaluated whether addition of a locking fluid containing 4% tetrasodium EDTA (t-EDTA) reduced central venous access device (CVAD) complications compared with usual care among adults in intensive care units (ICUs).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a0ea074be05d6e3efb5f320 https://doi.org/10.1001/jama.2026.7399

View Full Paper

Ask AI

Bookmark

Share

4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

Key Points

Implication

Abstract

Discussion

Cite This Study

4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading